Pharmacists and biotechnologists of all countries, unite!
The top 20 pharmaceutical companies in the world will compete for contracts at BIO-Europe 2009
I.G. Dranin, Pharma2020, based on the materials of Pharmacy ChoiceThe management teams of the largest companies will take part in BIO-Europe 2009, the largest conference on the problem, opening on November 24 in Vienna.
Representatives of Abbott, Amgen, Astellas Pharma, AstraZeneca, Baxter, Bayer HealthCare/Bayer Schering Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKline, Johnson&Johnson, Merck&Co, Merck Serono, Novartis, Pfizer, Roche, Sanofi Aventis, Takeda Pharmaceutical Co., Teva Pharmaceutical Industries, etc., will attend the conference to explore industry issues, explore new business approaches, and, most importantly, a modern network of biotechnologies in relation to their commercial plans
For biotech companies, the positive dynamics is that Big Pharma today is fully loaded with work and more and more recognizes biological products. The adventurous partnerships of the early 80s gave way to solid strategic alliances and thoughtful acquisitions. Today, almost all pharmaceutical companies have created their own biotechnological programs or biovenchure divisions to find and finance promising start-ups. Over the past 10 years, about 75% of the cases of liquidation of private biotech firms have been caused by takeover by larger firms, rather than through an IPO.
"The speed at which changes are taking place within Big Pharma is incredible compared to the middle of the last decade," writes William Ringo, Pfizer's senior vice president for global business development, strategies and innovation, in the latest edition of partneringNEWS. "Look at our takeover of Wyeth: one of its key reasons was the need to delve into biopharmaceuticals. This is an important area for us because of patent protection, biosimilar capabilities, as well as creating a balanced product portfolio. I believe that Big Pharma has been passionate about "small molecules" for a long time because of high profit levels, low-cost production and huge advantages. Now we have more research centers, and we are well aware of the importance of partnership with biotech companies."
From the perspective of venture capital, the lack of an IPO means that companies that have chosen an early partnership strategy are most likely to be sponsored. A company created "for takeover" after confirming the concept of its leading candidate drug (usually a successful phase 2 clinical trial) may be significantly smaller than the one that undertakes to obtain permission, launch and marketing. Thus, venture investors can contribute proportionally less money and get a return faster. This year's event in Vienna will continue the 15-year tradition of holding high-quality partner meetings and informative meetings. Considering the arrival of more than 2,500 delegates from 1,350 companies from 50 countries expected at BIO-Europe 2009, industry leaders know well where the partnership begins.
Portal "Eternal youth" http://vechnayamolodost.ru
25.09.2009